STABRELLE
DEAD

Serial Number

87522219

Owner

ALLERGAN FINANCE, LLC

Filing Date

Jul 10, 2017

Add to watchlist:

No watchlists yet
View on USPTO

STABRELLE Trademark

Serial Number: 87522219

STABRELLE is a trademark filed by ALLERGAN FINANCE, LLC on July 10, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN FINANCE, LLC (37 trademarks)

400 INTERPACE PARKWAY
PARSIPPANY, NJ 07054

Entity Type: 16

Trademark Details

Filing Date

July 10, 2017

Registration Date

Not Registered

Published for Opposition

December 5, 2017

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical blood therapy preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 8, 2021 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 8, 2021 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 13, 2020 EXRA
SOU EXTENSION 5 GRANTED
Aug 12, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 12, 2020 AITU
SOU EXTENSION 5 FILED
Jul 24, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 24, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 28, 2020 EXRA
SOU EXTENSION 4 GRANTED
Jan 24, 2020 EX4G
SOU EXTENSION 4 FILED
Jan 24, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 24, 2020 EEXT
ASSIGNED TO EXAMINER
Jul 8, 2019 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2019 EXRA
SOU EXTENSION 3 GRANTED
Jun 14, 2019 EX3G
SOU EXTENSION 3 FILED
Jun 14, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 14, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 25, 2019 EXRA
SOU EXTENSION 2 GRANTED
Jan 23, 2019 EX2G
SOU EXTENSION 2 FILED
Jan 23, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 23, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 21, 2018 EXRA
SOU EXTENSION 1 GRANTED
Jul 19, 2018 EX1G
SOU EXTENSION 1 FILED
Jul 19, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 19, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 30, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2017 NPUB
PUBLISHED FOR OPPOSITION
Dec 5, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2017 NONP
ASSIGNED TO LIE
Oct 30, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 13, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 13, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 13, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 13, 2017 CNEA
ASSIGNED TO EXAMINER
Oct 5, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 16, 2017 NWOS
NEW APPLICATION ENTERED
Jul 13, 2017 NWAP